COMMUNIQUÉS West-GlobeNewswire

Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026
31/03/2026
JERUSALEM, March 31, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd . (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® today announced that an abstract [...]
Wildfire Smoke is Coming; Millions of Canadian Lungs Aren’t Ready
31/03/2026
Lung Health Foundation urges people with asthma and COPD to prepare their Action Plans now before air quality deteriorates TORONTO, March 31, 2026 (GLOBE NEWSWIRE) -- Canada is entering another wildfire season -- and [...]
MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
31/03/2026
Potential breakthrough therapeutic targets $50B+ global immunotherapy market 1 CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage [...]
Lumina Therapy Alliance Expands National Footprint with Addition of The Therapy Group of DC, Reaching Nearly 400 Clinicians Nationwide
31/03/2026
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Lumina Therapy Alliance , a growing national network of premier, in-person mental health practices, today announced that The Therapy Group of DC has joined its alliance. With [...]
Trethera Announces Massachusetts General Hospital Clinical Trial Collaboration to Evaluate TRE-515 in ALS Patients
31/03/2026
LOS ANGELES, March 31, 2026 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer, autoimmune, and neuroimmune diseases, today [...]
Lighthouse Autism Center Opening New Autism Therapy Center in Rocky Mount, North Carolina
31/03/2026
ROCKY MOUNT, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Lighthouse Autism Center (LAC), a leading provider of center-based autism therapy, is proud to announce the opening of a new autism therapy center in Rocky Mount, [...]
TimelyCare Lands Fifth Straight Appearance on Inc. Fastest-Growing Companies in the Southwest list
31/03/2026
Companies on the Inc. Regionals: Southwest list had a median growth rate of 79% Fort Worth, TX, March 31, 2026 (GLOBE NEWSWIRE) -- Inc., a leading media company focused on entrepreneurs and business leaders shaping our [...]
Spinal Rehab & Sports Medicine Expands Impact in Austin with Elite University Partnerships and Growing Presence Across Local Athletic Communities
31/03/2026
AUSTIN, Texas, March 31, 2026 (GLOBE NEWSWIRE) -- As Austin continues to emerge as one of the nation’s most active and athletic cities, Spinal Rehab & Sports Medicine is making headlines for its expanding influence [...]
Axiom Medical Signal Summit 2026 Showcases the Power of Early Action and Complete Case Management
31/03/2026
Annual event recognizes client organizations advancing workforce health through early reporting, measurable outcomes, and strong partnership HOUSTON, TX, March 31, 2026 (GLOBE NEWSWIRE) -- Axiom Medical brought clients [...]
Betterbrand's BetterLungs Mullein + Chlorophyll Shows Significant Respiratory and Fatigue Improvements in 60-Day Clinical Study
31/03/2026
Triple-blind, placebo-controlled Citruslabs trial shows statistically significant improvements in breathing comfort, mucus clearance, and energy levels across 100 participants AUSTIN, Texas, March 31, 2026 (GLOBE [...]
BiomX Obtains Option to Acquire Control of Israeli Laser-Radar Counter-Drone System
31/03/2026
The platform delivers ~99% accuracy in real-world deployments across defense and infrastructure; When closed, the transaction value is estimated at approximately $45 million NETANYA, Israel, March 31, 2026 (GLOBE [...]
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
31/03/2026
ZUG, Switzerland, March 31, 2026 (GLOBE NEWSWIRE) -- PRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the importance and urgency of addressing optic neuritis, a serious [...]
LENSAR® Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
31/03/2026
15 ALLY Robotic Cataract Laser Systems® (“ALLY Systems”) placed in 4Q 2025; Backlog of 13 ALLY Systems pending installation as of December 31, 2025 ALLY installed base grew 48%, total laser installed base grew 13% over [...]
Beta Bionics Introduces Bionic Insights™ in Bionic Reports — Transforming How Clinicians Understand and Optimize Diabetes Care
31/03/2026
Advanced report intelligence delivers actionable guidance to improve outcomes for people using the iLet Bionic Pancreas IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Beta Bionics today announced the launch of [...]
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31/03/2026
RESEARCH TRIANGLE PARK, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on March 17, [...]
KDIGO publishes 2026 Clinical Practice Guideline Draft for Acute Kidney Injury and Acute Kidney Disease
31/03/2026
March 31, 2026 News Release KDIGO publishes 2026 Clinical Practice Guideline Draft for Acute Kidney Injury and Acute Kidney Disease COPENHAGEN, DENMARK, 31 March 2026 – BioPorto A/S (“BioPorto” or “Company”) (CPH: [...]
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
31/03/2026
PXL-770 (now SCY-770) is a clinical stage, well-characterized oral therapy designed to address the underlying drivers of ADPKD by reducing cyst growth and disease progression A Phase 2 proof-of-concept study of SCY-770 [...]
SCYNEXIS Announces $40.0 Million Private Placement
31/03/2026
JERSEY CITY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies to address severe rare diseases [...]
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
31/03/2026
Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI ® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE ® FDA-approved in geographic [...]

Pages